Page 1244 - Saunders Comprehensive Review For NCLEX-RN
P. 1244

abnormalities. If prescribed, the client needs to follow strict rules of the
                                                iPLEDGE program. It must not be used if the client is pregnant.
                                        F. iPLEDGE program

                                             1. A risk management program that ensures that no
                                                woman starting isotretinoin is pregnant and that no
                                                woman taking this medication becomes pregnant;
                                                refer to American Academy of Dermatology
                                                Association at
                                                https://www.aad.org/public/diseases/acne-and-
                                                rosacea/isotretinoin-treatment-for-severe-acne
                                             2. Access to the medication is controlled through a
                                                central automated system.
                                             3. Strict rules must be followed by the client, PHCP
                                                prescribing the medication, pharmacist dispensing
                                                the medication, and wholesaler of the medication to
                                                ensure safety and to ensure that no woman is
                                                pregnant on initiation of therapy or becomes pregnant
                                                while taking the medication.
                                             4. Also see iPLEDGE® program at
                                                https://www.ipledgeprogram.com/iPledgeUI/home.u
                                G. Hormonal medications
                                             1. Hormonal medications such as oral contraceptives and
                                                spironolactone may be prescribed to treat acne in
                                                female clients.
                                             2. These medications decrease androgen activity,
                                                resulting in decreased production of sebum.
                                             3. Spironolactone is teratogenic; therefore, contraception
                                                during its use is necessary.
                                             4. Side and adverse effects of spironolactone include
                                                breast tenderness, menstrual irregularities, and
                                                hyperkalemia.
                    VIII. Burn Products: (Box 43-6) Refer to Chapter 69 for information on Caring
                       for the Burn Client
                                A. Silver sulfadiazine
                                             1. Has broad spectrum of activity against gram-negative
                                                bacteria, gram-positive bacteria, and yeast
                                             2. Silver is released slowly from the cream, which is
                                                selectively toxic to bacteria.
                                             3. Used primarily to prevent sepsis in clients with burns
                                             4. Not a carbonic anhydrase inhibitor; does not cause
                                                acidosis
                                             5. Apply 1⁄16-inch film (keep burn covered at all times
                                                with silver sulfadiazine).
                                             6. Side and adverse effects include rash and itching,
                                                blue-green or gray skin discoloration, leukopenia, and
                                                interstitial nephritis.
                                             7. Monitor complete blood cell count, particularly the



                                                         1244
   1239   1240   1241   1242   1243   1244   1245   1246   1247   1248   1249